Yu, P., Xu, X., Zhang, J., Xia, X., Xu, F., Weng, J., . . . Shen, Y. Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway. Wiley.
Chicago Style (17th ed.) CitationYu, Peng, Xi Xu, Jing Zhang, Xuan Xia, Fen Xu, Jianping Weng, Xiaoyang Lai, and Yunfeng Shen. Liraglutide Attenuates Nonalcoholic Fatty Liver Disease Through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway. Wiley.
MLA (9th ed.) CitationYu, Peng, et al. Liraglutide Attenuates Nonalcoholic Fatty Liver Disease Through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway. Wiley.
Warning: These citations may not always be 100% accurate.